-
1.发明授权INHIBITORS OF IgG-A2BG2 FOR USE IN TREATING AND DIAGNOSING AMYOTROPHIC LATERAL SCLEROSIS 有权IgG-A2BG2抑制剂用于治疗和诊断AMYOTROPHIC LATERAL SCLEROSIS
公开(公告)号：EP2788017B1
公开(公告)日：2017-05-31
申请号：EP12813991.2
申请日：2012-12-04
IPC分类号： A61K38/47 , A61K39/395 , A61P25/28
CPC分类号： A61K38/47 , A61K31/428 , C07K16/00 , C07K16/4283 , C07K2317/41 , C07K2317/52 , C07K2317/732 , G01N33/6854 , G01N33/6896 , G01N2800/28
摘要： The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject.
摘要翻译： 本发明提供了治疗受试者的肌萎缩性侧索硬化症的发作，延缓其发作，延缓其发展，降低其发生率或降低其严重程度的方法，所述方法包括向受试者施用干扰IgG-A2BG2表达的药剂 ，IgG-A2BG2功能或IgG-A2BG2与所述受试者中的CD16相互作用。
-
2.发明公开DIAGNOSTIC AND THERAPEUTIC METHODS AND THEIR APPLICATION IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) 有权抑制剂VON IgG-A2BG2 ZUR BEHANDLUNG UND DIORNOSE VON AMYOTROPHISCHER LATERALSKLEROSE
公开(公告)号：EP2788017A1
公开(公告)日：2014-10-15
申请号：EP12813991.2
申请日：2012-12-04
发明人： PORGADOR, Angel
IPC分类号： A61K38/47 , A61K39/395 , A61P25/28
CPC分类号： A61K38/47 , A61K31/428 , C07K16/00 , C07K16/4283 , C07K2317/41 , C07K2317/52 , C07K2317/732 , G01N33/6854 , G01N33/6896 , G01N2800/28
摘要： The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject.
摘要翻译： 本发明提供了治疗，延缓发作，延缓进展，减少受试者的肌萎缩性侧索硬化的发生或降低其严重程度的方法，所述方法包括向受试者施用干扰IgG-A2BG2表达的药剂 ，IgG-A2BG2功能或IgG-A2BG2与所述受试者中CD16的相互作用。
-
公开(公告)号：EP2828291A1
公开(公告)日：2015-01-28
申请号：EP13718407.3
申请日：2013-03-14
申请人： Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. , Ben-Gurion University of The Negev Research and Development Authority
发明人： PORGADOR, Angel , MANDELBOIM, Ofer
IPC分类号： C07K14/705
CPC分类号： C07K14/705 , A61K38/00 , C07K7/06 , C07K7/08
摘要： The invention relates to use of specific peptides derived from the cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. The invention further relates to compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
摘要翻译： 本发明涉及来源于细胞毒性受体NKp46的特定肽在预防和治疗糖尿病（包括I型糖尿病（TID）和2型糖尿病）中的用途。 本发明进一步涉及包含NKp46细胞外区片段的组合物，用于预防糖尿病的发作和发展。
-
公开(公告)号：EP2408468B1
公开(公告)日：2014-04-30
申请号：EP10714095.6
申请日：2010-03-18
申请人： Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. , Hadasit Medical Research Services And Development Ltd. , Ben-Gurion University Of The Negev Research And Development Authority
IPC分类号： A61K38/17 , C07K14/705 , C07K16/28 , A61P3/10
CPC分类号： A61K39/3955 , A61K38/00 , A61K2039/505 , C07K14/705 , C07K14/70503 , C07K16/2803 , C07K16/2851 , C07K2319/30
-
公开(公告)号：EP2408468A2
公开(公告)日：2012-01-25
申请号：EP10714095.6
申请日：2010-03-18
申请人： Yissum Research Development Company of the Hebrew University of Jerusalem , Hadasit Medical Research Services And Development Ltd. , Ben-Gurion University Of The Negev Research And Development Authority
IPC分类号： A61K38/17
CPC分类号： A61K39/3955 , A61K38/00 , A61K2039/505 , C07K14/705 , C07K14/70503 , C07K16/2803 , C07K16/2851 , C07K2319/30
摘要： The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
-
-
-
-
搜索结果
5 条记录 (耗时 0.016 秒)
